Literature DB >> 16123691

HIV drug resistance and HIV transmission risk behaviors among active injection drug users.

Michael J Kozal1, K Rivet Amico, Jennifer Chiarella, Deborah Cornman, William Fisher, Jeffrey Fisher, Gerald Friedland.   

Abstract

HIV(+) injection drug users in clinical care may harbor and transmit drug-resistant HIV. We performed a retrospective study of HIV drug resistance and risk behavior among HIV(+) injection drug users in care to determine the number of needle-sharing events that involved and the proportion of sharing partners exposed to drug-resistant HIV. Among 180 HIV injection drug users, 55 (31%) reported injecting drugs in the previous month, and 22 of these (40%) shared needles and/or works 148 times with 296 partners, of whom 271 (92%) were thought to be HIV(-) or status unknown. Further, 55 (31%) drug users harbored resistant HIV, including 5 (3% of total) who also shared needles and/or works a total of 27 times with 44 partners (18% of all sharing events and 15% of all exposed partners). A small proportion of injection drug users receiving clinical care engage in injection risk behavior and carry resistant HIV; however, because of multiple partners and needle-sharing events, they expose a substantial number of individuals to drug-resistant HIV. Strategies to reduce injection drug use risk behaviors among patients in clinical care are needed to reduce the transmission of sensitive and resistant HIV.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16123691     DOI: 10.1097/01.qai.0000159666.95455.d2

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.731


  10 in total

1.  Rationale and design of an integrated bio-behavioral approach to improve adherence to pre-exposure prophylaxis and HIV risk reduction among opioid-dependent people who use drugs: The CHRP-BB study.

Authors:  Roman Shrestha; Frederick L Altice; Brian Sibilio; Jude Ssenyonjo; Michael M Copenhaver
Journal:  Contemp Clin Trials       Date:  2019-06-20       Impact factor: 2.226

2.  Initiation, adherence, and retention in a randomized controlled trial of directly administered antiretroviral therapy.

Authors:  Duncan Smith-Rohrberg Maru; R Douglas Bruce; Mary Walton; Jo Anne Mezger; Sandra A Springer; David Shield; Frederick L Altice
Journal:  AIDS Behav       Date:  2007-12-18

3.  Directly administered antiretroviral therapy for HIV-infected drug users does not have an impact on antiretroviral resistance: results from a randomized controlled trial.

Authors:  Duncan Smith-Rohrberg Maru; Michael J Kozal; R Douglas Bruce; Sandra A Springer; Frederick L Altice
Journal:  J Acquir Immune Defic Syndr       Date:  2007-12-15       Impact factor: 3.731

4.  Depression and symptomatic response among HIV-infected drug users enrolled in a randomized controlled trial of directly administered antiretroviral therapy.

Authors:  Sandra A Springer; Shu Chen; Frederick Altice
Journal:  AIDS Care       Date:  2009-08

5.  HIV treatment outcomes among HIV-infected, opioid-dependent patients receiving buprenorphine/naloxone treatment within HIV clinical care settings: results from a multisite study.

Authors:  Frederick L Altice; R Douglas Bruce; Gregory M Lucas; Paula J Lum; P Todd Korthuis; Timothy P Flanigan; Chinazo O Cunningham; Lynn E Sullivan; Pamela Vergara-Rodriguez; David A Fiellin; Adan Cajina; Michael Botsko; Vijay Nandi; Marc N Gourevitch; Ruth Finkelstein
Journal:  J Acquir Immune Defic Syndr       Date:  2011-03-01       Impact factor: 3.731

6.  A population-based and longitudinal study of sexual behavior and multidrug-resistant HIV among patients in clinical care.

Authors:  Michael J Kozal; K Rivet Amico; Jennifer Chiarella; Deborah Cornman; William Fisher; Jeffrey Fisher; Gerald Friedland
Journal:  MedGenMed       Date:  2006-06-13

7.  Association between risk behaviors and antiretroviral resistance in HIV-infected patients receiving opioid agonist treatment.

Authors:  Jeanette M Tetrault; Michael J Kozal; Jennifer Chiarella; Lynn E Sullivan; An T Dinh; David A Fiellin
Journal:  J Addict Med       Date:  2013 Mar-Apr       Impact factor: 3.702

8.  Long-acting parenteral nanoformulated antiretroviral therapy: interest and attitudes of HIV-infected patients.

Authors:  Jennifer Williams; Harlan R Sayles; Jane L Meza; Patrick Sayre; Uriel Sandkovsky; Howard E Gendelman; Charles Flexner; Susan Swindells
Journal:  Nanomedicine (Lond)       Date:  2013-04-23       Impact factor: 5.307

Review 9.  Update in HIV care.

Authors:  Gail Berkenblit; Lynn Sullivan; James Sosman; Allen Gifford; Joseph Cofrancesco
Journal:  J Gen Intern Med       Date:  2007-02       Impact factor: 5.128

10.  Changes from 2000 to 2009 in the Prevalence of HIV-1 Containing Drug Resistance-Associated Mutations from Antiretroviral Therapy-Naive, HIV-1-Infected Patients in the United States.

Authors:  Lisa L Ross; Denise Shortino; Mark S Shaefer
Journal:  AIDS Res Hum Retroviruses       Date:  2018-06-05       Impact factor: 2.205

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.